Evidence map›Paper›PMID 26987353›Full record

ArticleStem cells translational medicine2016

Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis.

Jeffrey Kiernan, Sally Hu, Marc D Grynpas, John E Davies, William L Stanford

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Classes of Stem Cells: From Biology to Engineering.Regenerative engineering and translational medicine · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jeffrey KiernanInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Sally HuDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Marc D GrynpasDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
John E DaviesInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada wstanford@ohri.ca jed.davies@utoronto.ca.
William L StanfordInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada Sprott Centre for Stem Cell Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada Department of Cellular and Molecular Medicine and Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada wstanford@ohri.ca jed.davies@utoronto.ca.
University of Toronto · CALunenfeld-Tanenbaum Research Institute · CAOttawa Hospital · CA

Funding

Canadian Institutes of Health Research FRN 62788
6 · The paper itself

Abstract

unlabelledAge-related osteoporosis is driven by defects in the tissue-resident mesenchymal stromal cells (MSCs), a heterogeneous population of musculoskeletal progenitors that includes skeletal stem cells. MSC decline leads to reduced bone formation, causing loss of bone volume and the breakdown of bony microarchitecture crucial to trabecular strength. Furthermore, the low-turnover state precipitated by MSC loss leads to low-quality bone that is unable to perform remodeling-mediated maintenance--replacing old damaged bone with new healthy tissue. Using minimally expanded exogenous MSCs injected systemically into a mouse model of human age-related osteoporosis, we show long-term engraftment and markedly increased bone formation. This led to improved bone quality and turnover and, importantly, sustained microarchitectural competence. These data establish proof of concept that MSC transplantation may be used to prevent or treat human age-related osteoporosis. SIGNIFICANCE: This study shows that a single dose of minimally expanded mesenchymal stromal cells (MSCs) injected systemically into a mouse model of human age-related osteoporosis display long-term engraftment and prevent the decline in bone formation, bone quality, and microarchitectural competence. This work adds to a growing body of evidence suggesting that the decline of MSCs associated with age-related osteoporosis is a major transformative event in the progression of the disease. Furthermore, it establishes proof of concept that MSC transplantation may be a viable therapeutic strategy to treat or prevent human age-related osteoporosis.

Indexed as

Mesenchymal Stem Cell TransplantationOsteogenesisAnimalsAtaxin-1BiomarkersBone and BonesCells, CulturedCell SeparationCell SurvivalDisease Models, AnimalGraft SurvivalMesenchymal Stem CellsMice, KnockoutOsteoporosisPhenotypeTime FactorsAtaxin-1Atxn1 protein, mouseBiomarkersMesenchymal stem cellOsteoporosisSca-1Stem cell transplantationTissue-specific stem cells

Identifiers

PMID26987353
PMCPMC4835247
OpenAlexW2301896334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.